NASDAQ:MRTX - Mirati Therapeutics, Inc.
$71.74
 $-1.11
-1.52%
2:30PM EDT
2019-02-15
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MRTX     avg for
industry  
  avg for
sector  
42 stocks weight:  146. 74   0. 00   0. 00  
42 stocks rank:  1. 30 K 1. 86 K 1. 09 K
# analyst opinions:  9. 00   14. 92   14. 43  
mean recommendation:  1. 80   1. 91   1. 93  

quick ratio:  11. 14   5. 37   1. 81  
current ratio:  11. 22   5. 69   2. 19  

target price low:  37. 00   88. 97   117. 82  
target price avg:  65. 22   115. 19   141. 96  
target price high:  80. 00   143. 40   163. 16  
1-yr high:  72. 85   124. 30   142. 77  
last close:  72. 85   101. 85   127. 84  
50-day avg:  53. 92   98. 27   122. 46  
200-day avg:  48. 81   99. 72   122. 70  
1-yr low:  26. 05   78. 19   100. 16  
volume:  335. 07 K 2. 38 M 4. 64 M
50-day avg volume:  615. 20 K 3. 31 M 4. 94 M
200-day avg volume:  588. 73 K 3. 23 M 4. 28 M

1-day return:  0. 91 % 0. 22 % 0. 48 %
this week return:  3. 42 % 1. 77 % 2. 01 %
12-wk return:  82. 17 % 6. 56 % 3. 33 %
52-wk return:  148. 16 % -2. 23 % 14. 35 %

enterprise value (EV):  2. 05 B 55. 17 B 104. 51 B
market cap:  2. 49 B 49. 01 B 96. 46 B
EBITDA:  -91. 01 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -22. 49   -91. 79   2. 29  
enterprise/revenue (EV/R):  216. 18   29. 84   23. 39  
total revenue:  9. 47 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -88. 04 M 2. 37 B 3. 58 B

shares outstanding:  34. 13 M 607. 99 M 1. 22 B
shares:  18. 88 M 605. 53 M 1. 15 B
shares short:  5. 49 M 11. 62 M 12. 55 M
shares short prior month:  4. 76 M 11. 95 M 13. 44 M
short ratio:  6. 62   4. 82   3. 10  
short % of float:  22. 50 % 6. 19 % 2. 82 %
total cash/share:  7. 50   12. 02   11. 46  
total cash:  243. 90 M 7. 41 B 7. 37 B
free cash flow:  -34. 11 M 95. 99 M 2. 04 B
operating cash flow:  -63. 07 M 164. 74 M 3. 04 B

book value:  6. 92   14. 43   28. 26  
price/book:  10. 52   -1. 57   -2. 97  
operating margins:  -963. 17 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  100. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  18. 40 % --- ---
1-yr mean volatility:  0. 46 % 0. 01 % 0. 06 %

1-yr EPS:  -2. 99   3. 03   4. 09  
forward EPS:  -4. 00   4. 33   6. 99  
P/E:  -24. 39   6. 11   26. 91  
forward P/E:  -17. 61   8. 38   10. 48  
PE/G:  10. 99   0. 37   5. 61  
growth:  -2. 22 % 683. 72 % 104. 79 %
earnings high:  -0. 62   1. 27   1. 66  
earnings avg:  -0. 86   1. 01   1. 53  
earnings low:  -1. 02   0. 76   1. 40  
revenue high:  3. 00 M 2. 86 B 11. 19 B
revenue avg:  1. 19 M 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -34. 56 % -3. 27 % 3. 81 %
return on equity:  -60. 05 % 107. 48 % 27. 82 %
revenue/share:  0. 32   14. 68   59. 83  

beta (1yr vs S&P500):  1. 63   1. 21   0. 93  
sharpe (1yr):  1. 77   0. 06   0. 98  

held % insiders:  0. 94 % 6. 46 % 3. 21 %
held % institutions:  105. 08 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : MRTX
.    + 5.548 =         5.548 :: INITIAL WEIGHT
.  + 251.682 =        257.23 :: inverse volume-to-price addition
.  + 131.026 =       388.256 :: spline projection addition
.  - 126.656 =         261.6 :: poor performance penalty
.    x 2.588 =         677.0 :: one-year gains+dividend factor
.   x 10.036 =      6794.132 :: 13 weeks' performance factor
.    x 1.492 =     10140.167 :: industry recommendation factor
.    x 2.554 =      25897.26 :: symbol recommendation factor
.    x 4.296 =     111251.69 :: EV/R factor
.    x 0.997 =    110867.149 :: return on assets factor
.    x 0.994 =    110201.425 :: return on equity factor
.     x 2.03 =    223715.157 :: current ratio factor
.    x 1.048 =    234489.214 :: quick ratio factor
.    x 1.073 =    251577.248 :: short ratio factor
.    x 2.217 =    557744.216 :: price-to-book factor
.    x 1.472 =    821168.565 :: 5-day avg > 200-day avg
.    x 1.333 =    1094444.69 :: 5-day avg > 50-day avg
.    x 1.105 =   1209009.063 :: 50-day avg > 200-day avg
.    x 1.995 =   2411630.482 :: P/E weight
.    x 0.549 =   1324424.223 :: PE/G factor
.     x 1.55 =   2052354.757 :: beta factor
.    x 1.768 =   3627868.127 :: sharpe factor
.     x 0.93 =   3373371.932 :: target low factor
.    x 0.943 =   3179869.399 :: target mean factor
.    x 1.031 =   3279489.626 :: target high factor
.    x 1.066 =   3494666.145 :: industry 12-weeks return
.      x 1.0 =   3494432.503 :: overall "drift" factor
.    x 0.816 =   2851312.845 :: largest single-day jump factor
.     x 1.01 =   2879695.153 :: mean volatility factor
.    x 1.097 =   3159313.987 :: 42-day mean volatility factor
.      x 1.0 =   3159526.048 :: factor hist industry gain for week 06
.   cubeRoot =       146.737 :: reduced for readability
.                    146.737 :: FINAL WEIGHT for NASDAQ:MRTX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org